Based on the Adapthealth Corp stock forecast from 3 analysts, the average analyst target price for Adapthealth Corp is USD 12.38 over the next 12 months. Adapthealth Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adapthealth Corp is Slightly Bearish, which is based on 6 positive signals and 8 negative signals. At the last closing, Adapthealth Corp’s stock price was USD 10.63. Adapthealth Corp’s stock price has changed by -2.12% over the past week, -4.32% over the past month and +41.92% over the last year.
No recent analyst target price found for Adapthealth Corp
No recent average analyst rating found for Adapthealth Corp
Company Overview Adapthealth Corp
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania. Address: 220 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 Read Less
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individua...Read More
Frequently Asked Questions About Adapthealth Corp (AHCO) Stock
Based on ratings from 3 analysts Adapthealth Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on AHCO's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for AHCO is USD 12.38 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 10.5.
AHCO stock's Price/Earning ratio is 64.08.
Our analysis grades AHCO stock's Price / Earning ratio at F. This means that AHCO stock's Price/Earning ratio is above 70% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this AHCO may be a overvalued for its sector.
The last closing price of AHCO's stock was USD 10.63.
The most recent market capitalization for AHCO is USD 1.47B.
Based on targets from 3 analysts, the average taret price for AHCO is projected at USD 12.38 over the next 12 months.
This means that AHCO's stock price may go up by +16.42% over the next 12 months.
We can't find any ETFs which contains Adapthealth Corp's stock.
As per our most recent records Adapthealth Corp has 10,700 Employees.
Adapthealth Corp's registered address is 220 West Germantown Pike, Plymouth Meeting, PA, United States, 19462.
You can get more information about it from Adapthealth Corp's website at https://adapthealth.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Adapthealth Corp (AHCO) Stock
Based on ratings from 3 analysts Adapthealth Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on AHCO's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for AHCO is USD 12.38 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 10.5.
AHCO stock's Price/Earning ratio is 64.08.
Our analysis grades AHCO stock's Price / Earning ratio at F. This means that AHCO stock's Price/Earning ratio is above 70% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this AHCO may be a overvalued for its sector.
The last closing price of AHCO's stock was USD 10.63.
The most recent market capitalization for AHCO is USD 1.47B.
Based on targets from 3 analysts, the average taret price for AHCO is projected at USD 12.38 over the next 12 months.
This means that AHCO's stock price may go up by +16.42% over the next 12 months.
We can't find any ETFs which contains Adapthealth Corp's stock.
As per our most recent records Adapthealth Corp has 10,700 Employees.
Adapthealth Corp's registered address is 220 West Germantown Pike, Plymouth Meeting, PA, United States, 19462.
You can get more information about it from Adapthealth Corp's website at https://adapthealth.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AHCO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
